房颤口服抗凝患者行PCI的抗栓治疗:2018北美专家共识更新
该文为北美专家对房颤口服抗凝患者行经皮冠状动脉介入(PCI)抗栓管理的聚焦更新,基于2016年后关键临床试验结果,推荐优先选用非维生素K拮抗剂口服抗凝药而非维生素K拮抗剂,且多数患者出院时应采用口服抗凝药联合P2Y12抑制剂的双联治疗,仅高缺血/血栓且低出血风险者短期延长阿司匹林(三联治疗)。
要点
- 优先选择非维生素K拮抗剂口服抗凝药而非维生素K拮抗剂。
- 多数患者出院时采用口服抗凝药加P2Y12抑制剂双联治疗。
- 仅高缺血/血栓且低出血风险者短期用三联治疗。
核心结论
- 房颤口服抗凝患者行PCI后,优先选用非维生素K拮抗剂口服抗凝药而非维生素K拮抗剂。
- 多数患者出院时应采用口服抗凝药联合P2Y12抑制剂的双联治疗。
- 仅高缺血/血栓且低出血风险的选择性患者可短期延长阿司匹林(三联治疗)。
研究设计与样本
- 北美专家基于2016年后发表的关键临床试验结果制定的聚焦共识更新。
主要发现
- 关键临床试验评估了口服抗凝药类型和抗血小板治疗时长,支持上述推荐。
关键数值与推荐
- 优先使用非维生素K拮抗剂口服抗凝药而非维生素K拮抗剂。
- 多数患者出院时考虑双联治疗(口服抗凝药加P2Y12抑制剂单药抗血小板)。
- 仅高缺血/血栓且低出血风险的选择性患者短期延长阿司匹林(三联治疗)。
临床怎么用
- 房颤口服抗凝患者行PCI后,出院时默认双联抗栓,优选非维生素K拮抗剂口服抗凝药。
- 仅对高缺血/血栓且低出血风险者短期保留阿司匹林三联治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The optimal antithrombotic treatment regimen for patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation represents a challenge in clinical practice. In 2016, an updated opinion of selected experts from the United States and Canada on the treatment of patients with atrial fibrillation undergoing percutaneous coronary intervention was reported. After the 2016 North American consensus statement on the management of antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention, results of pivotal clinical trials assessing the type of oral anticoagulant agent and the duration of antiplatelet treatment have been published. On the basis of these results, this focused update on the antithrombotic management of patients with atrial fibrillation undergoing percutaneous coronary intervention recommends that a non-vitamin K antagonist oral anticoagulant be preferred over a vitamin K antagonist as the oral anticoagulant of choice. Moreover, a double-therapy regimen (oral anticoagulant plus single antiplatelet therapy with a P2Y12 inhibitor) by the time of hospital discharge should be considered for most patients, whereas extending the use of aspirin beyond hospital discharge (ie, triple therapy) should be considered only for selected patients at high ischemic/thrombotic and low bleeding risks and for a limited period of time. The present document provides a focused updated on the rationale for the new expert consensus-derived recommendations on the antithrombotic management of patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention.
引用
- Angiolillo DJ, Goodman SG, Bhatt DL, et al. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update. Circulation. 2018. PMID: 30571525. doi:10.1161/CIRCULATIONAHA.118.034722
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。